Rabid demand for weight-loss drugs like Ozempic and Wegovy is altering US society and transforming the healthcare industry. Rapid Response host Bob Safian guides us through the upheaval and lessons, talking with CEO Zach Reitano of Ro, a telehealth platform that has ridden the wave to a $7 billion valuation. Reitano shares why he chose obesity-treatment as his company’s “hero product,” the impact of weight-loss drugs on industries beyond health-care, and why the potential of GLP-1s like Ozempic mirrors that of AI.Read a transcript of this episode:&nbsp;<a href="https://mastersofscale.com/" rel="noopener noreferrer" target="_blank">https://mastersofscale.com</a>Subscribe to the Masters of Scale weekly newsletter:&nbsp;<a href="https://mastersofscale.com/subscribe" rel="noopener noreferrer" target="_blank">https://mastersofscale.com/subscribe</a>See Privacy Policy at <a href="https://art19.com/privacy" rel="noopener noreferrer" target="_blank">https://art19.com/privacy</a> and California Privacy Notice at <a href="https://art19.com/privacy#do-not-sell-my-info" rel="noopener noreferrer" target="_blank">https://art19.com/privacy#do-not-sell-my-info</a>.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

Riding the Ozempic wave, w/RO's CEO Zach Reitano

Masters of Scale